Understanding the Genetic
Architecture of Parkinson's Disease
The Global Parkinson’s Genetics Program (GP2) is an ambitious five-year program to genotype >150,000 volunteers around the world to further understand the genetic architecture of Parkinson’s disease (PD). There is still much to learn about genetic risk factors and the path to further understanding requires working collaboratively and openly sharing data, processes, and results.
Recruiting and investigating Parkinson’s disease patients with a potential monogenic basis.
Submit a Cohort
Collaborate with us and submit a cohort to GP2. Fill out our form to get started.
Check out the latest news about GP2.
Development is an important component of our program; our focus is to provide training and other funding opportunities for the next generation of Parkinson’s disease researchers around the world. GP2 will offer these opportunities to the entire neurodegeneration community through the course of the program.
Latest Blog Posts
Read the latest blogs from GP2’s scientists and collaborators.
GP2 and AMP PD: Platform Partners for Progress in Parkinson’s Research
Adding a layer of compute to connect two massive datasets is where we are headed. Mike Nalls, Hampton Leonard, Matt Bookman, and Eline Appelmans outline the partnership between The Global Parkinson’s Genetics Program (GP2) and Accelerating Medicines Partnership: Parkinson's Disease (AMP PD) to be your one-stop shop for PD genetic and genomic data in this new blog post.
What is Compliance and Why is it Important?
Members of the GP2 Operations and Compliance working group provide an overview of what compliance is and why it is important in GP2.
Members of the GP2 Complex Disease Data Analysis working group provide an overview of Genome-Wide Association Studies (GWAS), including statistical formulae, workflows, and examples from the most recent Parkinson’s disease GWAS.
Find out about GP2’s working groups and their recently accomplished milestones.